Nasdaq - Delayed Quote USD

Fidelity Select Pharmaceuticals Port (FPHAX)

22.95
+0.50
+(2.23%)
At close: 8:04:18 PM EDT

Top 9 Holdings (73.96% of Total Assets)

SymbolCompany% Assets
Eli Lilly and Company 24.89%
Novo Nordisk A/S 12.25%
AstraZeneca PLC 10.29%
GSK plc 5.63%
Gilead Sciences, Inc. 5.44%
Merck & Co., Inc. 5.29%
UCB SA 4.87%
Royalty Pharma plc 2.98%
Elanco Animal Health Incorporated 2.31%

Sector Weightings

SectorFPHAX
Healthcare   100.00%
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Overall Portfolio Composition (%)

Cash 3.39%
Stocks 95.13%
Bonds 0.09%
Others 1.39%
Preferred 0.00%
Convertible 0.00%

Bond Ratings

US Government 0.00%
AAA --
AA --
A --
BBB --
BB --
B --
Below B --
Other --

Equity Holdings

Average FPHAX Category Average
Price/Earnings 0.03 24.55
Price/Book 0.21 5.28
Price/Sales 0.2 2.06
Price/Cashflow 0.06 17.54
Median Market Cap 111,503.14 34,862.81
3 Year Earnings Growth 9.67 32.48

Bond Holdings

Average FPHAX Category Average
Maturity -- --
Duration 6 --
Credit Quality -- --

Performance & Risk

YTD Return -8.01%
5y Average Return 6.79%
Rank in Category (ytd) 22
% Rank in Category (ytd) --
Beta (5Y Monthly) 0.58
Morningstar Risk Rating

Fund Overview

Category Health
Fund Family Fidelity Investments
Net Assets 1.17B
YTD Return 1.90%
Yield 1.31%
Morningstar Rating
Inception Date Jun 18, 2001

Fund Summary

The fund normally invests at least 80% of assets in companies engaged in the research, development, manufacture, sale, or distribution of pharmaceuticals and drugs of all types. It invests in domestic and foreign issuers. The fund invests primarily in common stocks. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.

Related Tickers